SAN CARLOS, Calif.--September 23, 2026--Glycomine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GLM101 for the treatment of phosphomannomutase 2 congenital...
Eric Linsley will lead a discussion on "Partnering and Licensing in Neurotech" at the 2012 Neurotech Investing & Partnering Conference on May 21-22 in Boston.
News | 02. 21. 2012
Eric Linsley will lead a discussion on "Partnering and Licensing in Neurotech" at the 2012 Neurotech Investing & Partnering Conference on May 21-22 in Boston.
